Biohaven Ltd
Biohaven Ltd logo
BHVN

Biohaven Ltd (BHVN)

$18.811.46%

Market is closed
– opens on 8 PM, 30 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$18.385
Day's Range
$20.07
$5.54
52-Week Range
$20.07
1 month return30.9%
3 month return13.52%
1 year return85.84%
5 year return43.17%

Insights on Biohaven Ltd

  • Vs Vertex Pharmaceuticals, Inc.

    In the last 1 year, Vertex Pharmaceuticals, Inc. has given 32.3% return, outperforming this stock by 117.6%

  • Vs Moderna Inc

    In the last 3 years, Moderna Inc has given 38.3% return, outperforming this stock by 101.3%

Analyst Recommendation

based on 10 analysts ratings

Buy
90%
Buy
10%
Hold
0%
Sell

Based on 10 Wall street analysts offering stock ratings for Biohaven Ltd(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 28.65%

Current

$18.81

Target

$24.2

Recommendation Trend

Based on 10 analyst

Current1M Ago3M Ago
Buy
9
6
8
Hold
1
1
7
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization1.3B
Book Value$1.47
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-11.84
Wall Street Target Price24.2

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)10.22
Enterprise Value973.8M
Enterprise Value/Revenue0.0
Enterprise Value/Ebitda-2.41

Technicals

50 Day MA15.59
200 Day MA14.19

Institutional Holdings

Armistice Capital, LLC

2.1%

Marshall Wace Asset Management Ltd

1.89%

Millennium Management LLC

1.48%

HHG PLC

0.73%

Eventide Asset Management, LLC

0.73%

State Street Corporation

0.69%

Company Information

Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis.
OrganizationBiohaven Ltd
Employees0
CEODr. Vladimir Coric M.D.
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is Biohaven Ltd share price today?

Can Indians buy Biohaven Ltd shares?

How can I buy Biohaven Ltd shares from India?

Can Fractional shares of Biohaven Ltd be purchased?

What are the documents required to start investing in Biohaven Ltd stocks?

What are today’s High and Low prices of Biohaven Ltd?

What are today’s traded volumes of Biohaven Ltd?

What is today’s market capitalisation of Biohaven Ltd?

What is the 52 Week High and Low Range of Biohaven Ltd?

How much percentage Biohaven Ltd is down from its 52 Week High?

How much percentage Biohaven Ltd is up from its 52 Week low?

What are the historical returns of Biohaven Ltd?

Who is the Chief Executive Officer (CEO) of Biohaven Ltd?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*